Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs Mesoblast Limited — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $95.95, while Mesoblast Limited trades at $16.36 (market cap $2.17B). Which is the better fit depends on your goals.
| JNK | MESO | |
|---|---|---|
Sector | Fixed Income | Technology |
52-Week High | $98.19 | $20.96 |
52-Week Low | $94.66 | $12.88 |
Market Cap | — | $2.17B |
Enterprise Value | — | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK trades at $95.95, down slightly by 0.03% with a bearish technical outlook from moving averages and oscillators. The ETF shows consistent dividend payments but lacks key financial ratio data for fundamental assessment. Recent news highlights bond market volatility and investor focus on high-yield opportunities amid Federal Reserve uncertainty.
The outlook remains cautious due to technical weakness and macroeconomic pressures from potential rate hikes. Risks include fee erosion over time and sensitivity to interest rate changes, while the current yield may appeal to income-focused investors in a volatile market environment.
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
